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atriuretic Peptides
nd Cardiac Hypertrophy*
arry London, MD, PHD, FACC
ittsburgh, Pennsylvania
ardiac hypertrophy, an increase in the size and/or thick-
ess of the ventricles in the heart, is an important compen-
atory mechanism for pathophysiological states and an
ndependent predictor of cardiovascular morbidity and mor-
ality (1,2). Several studies have shown that left ventricular
ass in healthy populations and athletes is at least partially
enetically determined (3–5). At the cellular level, cardiac
ypertrophy results largely from an increase in the size of
ndividual cardiac myocytes. A number of molecular path-
ays related to hypertrophy have been studied in vitro and
n animal models, including the alpha- and beta-adrenergic
ervous systems, the renin-angiotensin-aldosterone system,
ndothelin-1, and calcineurin (6,7). Pharmacological block-
de of these pathways, to varying degrees, has proven beneficial
n the treatment of cardiovascular disorders, including heart
ailure. Polymorphisms in the adrenergic nervous system and
he renin-angiotensin-aldosterone system have been reported
o affect ventricular mass and/or hypertrophy, although the
ndings remain controversial (3,8,9).
See page 499
Atrial natriuretic peptide (ANP) and brain natriuretic
eptide (BNP) are produced by and stored in atrial and
entricular myocytes, respectively (10,11). Both peptides are
eleased in response to stretch and cleaved into an
-terminal peptide fragment (N-terminal proANP,
-terminal pro-BNP) and the active peptide. The peptides
ind to their receptors (mainly natriuretic peptide receptor
[NPRA], but also NPRB and NPRC), lead to vasodila-
ion and natriuresis, and are degraded by neutral endopep-
idase (NEP). Measurements of serum levels of the natri-
retic peptides and their N-terminal cleavage fragments
ave diagnostic and prognostic value in patients with known
r suspected heart failure. Infusions of nesiritide, a recom-
inant human BNP, improve hemodynamics and func-
ional status in patients with decompensated heart fail-
re, although the long-term safety and efficacy have been
uestioned (12,13).
The natriuretic peptides prevent cardiac myocyte hyper-
rophy in vitro (14). They also affect cardiac mass and left
entricular hypertrophy in animal models. In the spontane-
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or thep
merican College of Cardiology.
From the Cardiovascular Institute, University of Pittsburgh, Pittsburgh, Pennsylvania.usly hypertensive rat, a strong correlation was observed
etween blood pressure and a marker in Nppa, the gene that
ncodes for the ANP precursor peptide (15). No correlation
as found for Nppb, the gene that encodes for the BNP
recursor peptide. Targeted disruption of the proANP gene
n mice led to hypertension and hypertrophy in homozygous
nockouts and salt-sensitive hypertension in heterozygotes
16). Transgenic overexpression of ANP, on the other hand,
ended to protect against hypertrophic stimuli (17). Tar-
eted disruption of NprI, the gene encoding NPRA, also
aused hypertension and hypertrophy (18). Of note,
ardiac-specific overexpression of NPRA in NPRA knock-
ut mice decreased myocyte size without a decrease in blood
ressure, and in mice with a cardiac-restricted knockout of
prI, hypertrophy developed without hypertension (19,20).
his shows that NPRA receptors are present in the heart
nd transduce local antihypertrophic stimuli, analogous to
he renin-angiotensin system that is present in cardiac tissue
nd causes hypertrophy and fibrosis (21).
Several polymorphisms in the gene encoding for proANP
ave been reported, including the C664G promoter
ariant, the G1837A intronic variant, and the T2238C exon
coding variant (22). The rare C664G promoter poly-
orphism has been associated with hypertension in a
apanese population (23). The T2238C polymorphism dis-
upts the stop codon, extends ANP by two arginine resi-
ues, and has been associated with an increased risk of
troke and recurrent stroke (22). The ANP polymorphisms
ave also been associated with a lower risk of proteinuria
24). Of note, the three ANP polymorphisms are in linkage
isequilibrium. In addition, a deletion in the 5=-flanking
egion of the gene encoding NPRA has been associated
ith hypertension and hypertrophy (25).
In this issue of the Journal, Rubattu et al. (26) show an
ssociation between the 664G promoter polymorphism
nd left ventricular hypertrophy using echocardiography in a
ohort of 203 Italian patients with hypertension. The
ndings were not explained by differences in blood pressure
r by use of medications. Importantly, individuals in this
ohort and in a separate group of normotensive patients who
arried a copy of the variant allele had markedly decreased
roANP levels, providing a potential physiological basis for
he effect. An association was also found between a micro-
atellite marker genotype in the NPRA promoter and left
entricular mass. No associations were found with the other
olymorphisms in ANP or with a microsatellite marker at
he 3= end of the BNP gene.
These findings are potentially important for a number of
easons. They provide direct evidence of a role for the
atriuretic peptide system in the control of cardiac hyper-
rophy in humans. This could lead to a novel screen for the
enetic risk of hypertrophy, and potentially to trials of early
harmacological treatment in those patients with the hy-
ertrophic genotype. There are also potential pharmacoge-
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A number of factors limit the scope and impact of the
resent study. As pointed out by the investigators, another
ausal allele in linkage disequilibrium with the664G allele
annot be excluded. The 664G allele frequency is low,
hich limits any potential subgroup analysis and decreases
he clinical relevance of the polymorphism. The ethnic
omogeneity of the subjects reduces genetic and environ-
ental confounding variables, but makes generalization to
ther populations difficult. The study population was largely
ale, and it is not clear whether the findings are applicable
o women.
Even less can be said about the NPRA polynucleotide
epeat, for which no physiological support is presented and
hich may well be a marker for the causative polymorphism.
he findings presented here do not exclude variants in BNP
s determinants of hypertrophy. It is not known whether
olymorphisms in other genes related to the natriuretic
eptide degradation, such as NEP and NPRC, affect hy-
ertrophy (27). It is also not known whether modulating
ypertrophy via the natriuretic peptide system will decrease
he additional morbidity and mortality associated with
ypertrophy.
The study by Rubattu et al. (26) clearly highlights the
trengths and weaknesses of this type of association study.
lthough preliminary, the findings do suggest a potentially
ausal relationship between the promoter polymorphism
nd hypertrophy. To prove causality, additional studies on
he polymorphism need be performed in vitro and/or in
nimal models. In addition, the human studies should be
epeated in larger populations both to confirm the associa-
ion and to exclude other genes. Logically, one would
nticipate interactions between functional polymorphisms
n several genes in the natriuretic peptide pathways. Unfor-
unately, the number of subjects required for a complete
nalysis of interactions among the natriuretic system genes
ay be prohibitive.
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iovascular Institute, University of Pittsburgh, Scaife S572, 200
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